Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform

Despite the success of first, second, and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer with classical EGFR mutations (L858R or Exon 19 deletions), disease progression occurs due to the acquisition of T790M and C797S resista...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2024-12
Hauptverfasser:	Igawa, Hideyuki, Konst, Zef A, Therrien, Eric, Shelley, Mee, Koldsø, Heidi, Bos, Pieter H, Negri, Ana, Verras, Andreas, Guo, Jiaye, Dahlgren, Markus K, Levinson, Adam, Parr, Brendan T, Kurhade, Suresh E, Latthe, Prashant, Shetty, Rajesha, Santhanakrishnan, Sridhar, Amberg-Johnson, Katherine, Futran, Alan S, Atsriku, Christian, Pelletier, Robert D, Liu, Zhijian, Bell, Jeffrey A, Bhat, Sathesh, Svensson, Mats, Gerasyuto, Aleksey I
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!